The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) by Schaller Charles R since 2006.
The trader's CIK number is 903696.
At the time of the last reporting, Schaller Charles R was the Officer of Celldex Therapeutics, Inc.. (stock ticker symbol CLDX).
Also see all insider trading activities at Celldex Therapeutics, Inc..
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2008 | MEDX | 0 | $0 | 50,000 | $446,250 | 0 | $0 |
| 2007 | MEDX | 0 | $0 | 30,000 | $354,450 | 80,000 | $256,400 |
| 2006 | MEDX | 0 | $0 | 15,000 | $210,000 | 0 | $0 |
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2010 | CLDX | 5,000 | $17,250 | 0 | $0 | 0 | $0 |
| 2009 | CLDX | 17,000 | $84,505 | 0 | $0 | 0 | $0 |
| 2008 | CLDX | 3,000 | $18,330 | 0 | $0 | 0 | $0 |
2. Celldex Therapeutics, Inc. (CLDX)
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2008-03-28 | MEDX | Sale | 50,000 | 8.93 | 446,250 |
| 2007-06-15 | MEDX | Option Ex | 50,000 | 3.21 | 160,250 |
| 2007-03-20 | MEDX | Sale | 30,000 | 11.81 | 354,450 |
| 2007-03-20 | MEDX | Option Ex | 30,000 | 3.21 | 96,150 |
| 2006-03-17 | MEDX | Sale | 15,000 | 14.00 | 210,000 |
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2010-09-09 | CLDX | Buy | 5,000 | 3.45 | 17,250 |
| 2009-12-02 | CLDX | Buy | 7,000 | 4.68 | 32,795 |
| 2009-11-10 | CLDX | Buy | 10,000 | 5.17 | 51,710 |
| 2008-11-13 | CLDX | Buy | 3,000 | 6.11 | 18,330 |
Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Schaller Charles R (Officer of Celldex Therapeutics, Inc. at the time of this reporting) see the Securities and Exchange Commission (SEC) website.